PMID- 34093193
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210608
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Jiedu Tongluo Granules Ameliorates Post-stroke Depression Rat Model via 
      Regulating NMDAR/BDNF Signaling Pathway.
PG  - 662003
LID - 10.3389/fphar.2021.662003 [doi]
LID - 662003
AB  - Post-stroke depression (PSD) is one of the most common stroke complications, 
      which seriously affects stroke's therapeutic effect and brings great pain for 
      patients. The pathological mechanism of PSD has not been revealed. Jiedu Tongluo 
      granules (JDTLG) is an effective traditional Chinese medicine for PSD treatment 
      which is widely used in clinical treatment. JDTLG has a significant therapeutic 
      effect against PSD, but the mechanism is still unclear. The PSD rat model was 
      established by carotid artery embolization combined with chronic sleep 
      deprivation followed by treating with JDTLG. Neurobehavioral and neurofunctional 
      experiments were engaged in studying the neural function of rats. 
      Histomorphology, proteomics, and western blotting researches were performed to 
      investigate the potential molecular mechanisms related to JDTLG therapy. Oral 
      treatment of JDTLG could significantly improve the symptoms of neurological 
      deficit and depression symptoms of PSD rats. Proteomic analysis identified 
      several processes that may involve the regulation of JDTLG on the PSD animal 
      model, including energy metabolism, nervous system, and N-methyl-D-aspartate 
      receptor (NMDAR)/brain-derived neurotrophic factor (BDNF) signal pathway. Our 
      results showed that JDTLG could reduce glutamate (Glu) level and increase 
      gamma-aminobutyric acid (GABA) level via regulating the NMDAR/BDNF pathway, which 
      may play a vital role in the occurrence and development of PSD.
CI  - Copyright (c) 2021 Zhao, Ma, Xu, Yao, Zhang, Xue, Ren, Chang and Liu.
FAU - Zhao, Aimei
AU  - Zhao A
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - Graduate School, Beijing University of Chinese Medicine, Beijing, China.
FAU - Ma, Bo
AU  - Ma B
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
AD  - State Key Laboratory of Bioactive Substance and Function of Natural Medicines, 
      Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Xu, Li
AU  - Xu L
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Yao, Mingjiang
AU  - Yao M
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Zhang, Yehao
AU  - Zhang Y
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Xue, Bingjie
AU  - Xue B
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Ren, Junguo
AU  - Ren J
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
FAU - Chang, Dennis
AU  - Chang D
AD  - NICM, Western Sydney University, Penrith, NSW, Australia.
FAU - Liu, Jianxun
AU  - Liu J
AD  - Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of 
      Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical 
      Sciences, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210520
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8173625
OTO - NOTNLM
OT  - NMDAR/BDNF
OT  - jiedu tongluo granules
OT  - neuroprotection
OT  - post-stroke depression
OT  - traditional Chinese medicine
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/06/08 06:00
MHDA- 2021/06/08 06:01
PMCR- 2021/05/20
CRDT- 2021/06/07 05:49
PHST- 2021/01/31 00:00 [received]
PHST- 2021/04/28 00:00 [accepted]
PHST- 2021/06/07 05:49 [entrez]
PHST- 2021/06/08 06:00 [pubmed]
PHST- 2021/06/08 06:01 [medline]
PHST- 2021/05/20 00:00 [pmc-release]
AID - 662003 [pii]
AID - 10.3389/fphar.2021.662003 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 May 20;12:662003. doi: 10.3389/fphar.2021.662003. 
      eCollection 2021.